NYU Hospital for Joint Diseases Revenue and Competitors
Estimated Revenue & Valuation
- NYU Hospital for Joint Diseases's estimated annual revenue is currently $204.5M per year.
- NYU Hospital for Joint Diseases's estimated revenue per employee is $337,500
Employee Data
- NYU Hospital for Joint Diseases has 606 Employees.
- NYU Hospital for Joint Diseases grew their employee count by -3% last year.
NYU Hospital for Joint Diseases's People
Name | Title | Email/Phone |
---|
NYU Hospital for Joint Diseases Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $54.4M | 183 | 6% | N/A | N/A |
#2 | $18M | 74 | -4% | N/A | N/A |
#3 | $162.7M | 482 | 39% | N/A | N/A |
#4 | $42.8M | 144 | 8% | N/A | N/A |
#5 | $26.5M | 98 | 4% | N/A | N/A |
#6 | $33.2M | 123 | -2% | N/A | N/A |
#7 | $29.7M | 110 | 12% | N/A | N/A |
#8 | $15.5M | 66 | -21% | $29.7M | N/A |
#9 | $1645.8M | 4354 | 13% | N/A | N/A |
#10 | $43.7M | 147 | 18% | N/A | N/A |
What Is NYU Hospital for Joint Diseases?
Learn about working at NYU Hospital for Joint Diseases. Join LinkedIn today for free. See who you know at NYU Hospital for Joint Diseases, leverage your professional network, and get hired.
keywords:N/AN/A
Total Funding
606
Number of Employees
$204.5M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NYU Hospital for Joint Diseases News
2022-04-13 - NIH Expands Autoimmune Research to Include More ...
... Lady Va Maughan Professor of Rheumatology at NYU Langone Health, ... Each disease team will represent from four to as many as 10 sites,...
2022-03-30 - NYU Langone joins NIH-sponsored program as leading center to discover new
targets for autoimmune, inflammatory diseases
NYU Langone Health is joining a new National Institutes of Health ... psoriatic disease will have biopsies of the skin and joint synovium to...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $35M | 606 | 7% | N/A |
#2 | $265.1M | 606 | 3% | N/A |
#3 | $185.6M | 606 | 7% | N/A |
#4 | $136.4M | 606 | 6% | N/A |
#5 | $35M | 607 | 5% | N/A |